Viral vectors as vaccine platforms: from immunogenicity to impact (Q24574798)

title

Viral vectors as vaccine platforms: from immunogenicity to impact (English)

0 references

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27286566%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Alexandra Spencer

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27286566%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Adrian V. S. Hill

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27286566%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

2

Teresa Lambe

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27286566%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

3

Christine S Rollier

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27286566%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

6

Lucy Dorrell

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27286566%20AND%20SRC:MED&resulttype=core&format=json

Current Opinion in Immunology

8 June 2020

language of work or name

English

0 references

publication date

August 2016

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27286566%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

volume

41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27286566%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

page(s)

47-54

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27286566%20AND%20SRC:MED&resulttype=core&format=json

Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells

8 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Adenoviral Vector Vaccination Induces a Conserved Program of CD8(+) T Cell Memory Differentiation in Mouse and Man.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, doub

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Fusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

1 reference

7 January 2021

Immune clearance of highly pathogenic SIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Carbohydrate-based ice recrystallization inhibitors increase infectivity and thermostability of viral vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Efficacy of high-dose versus standard-dose influenza vaccine in older adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Efficacy of a tetravalent dengue vaccine in children in Latin America.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Merck Ad5/HIV induces broad innate immune activation that predicts CD8⁺ T-cell responses but is attenuated by preexisting Ad5 immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Challenges in manufacturing adenoviral vectors for global vaccine product deployment

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Broadly targeted CD8⁺ T cell responses restricted by major histocompatibility complex E.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Vaccination to conserved influenza antigens in mice using a novel Simian adenovirus vector, PanAd3, derived from the bonobo Pan paniscus

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class ii invariant chain

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

New Japanese encephalitis vaccines: alternatives to production in mouse brain

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

Enhancing poxvirus vectors vaccine immunogenicity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.05.014

7 January 2021

10.1016/J.COI.2016.05.014

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27286566%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

1 reference